Back to top
more

Ultragenyx Pharmaceutical (RARE)

(Delayed Data from NSDQ)

$50.36 USD

50.36
1,246,770

-0.07 (-0.14%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $50.32 -0.04 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Earnings Preview: Ultragenyx (RARE) Q3 Earnings Expected to Decline

by Zacks Equity Research

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up

by Zacks Equity Research

Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -31.40% and 0.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) Provides Update From Angelman Syndrome Study

by Zacks Equity Research

Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.

Ultragenyx (RARE) Sells Portion of Royalty Interest for $500M

by Zacks Equity Research

Ultragenyx (RARE) sells 30% of the royalty interest receivable on future North America sales of Crysvita for $500 million. The total payments are capped at 1.45 times the purchase price.

Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout

by Zacks Equity Research

Shares of Mereo BioPharma (MREO) surge after reports suggest that AstraZeneca (AZN) is interested in acquiring it.

Ionis' (IONS) Angelman Syndrome Drug Gets FDA's Orphan Tag

by Zacks Equity Research

The FDA grants orphan drug and rare pediatric disease designations to Ionis' (IONS) ION582 for treating Angelman syndrome. These designations will help incentivize development of the candidate.

Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate

by Zacks Equity Research

Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.

Ultragenyx's (RARE) Q1 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.

Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -24.43% and 5.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) Begins Dosing in Pivotal Study on Setrusumab

by Zacks Equity Research

Ultragenyx (RARE) doses the first patient in a pivotal phase II/III study evaluating setrusumab (UX143) for the treatment of osteogenesis imperfecta.

Ultragenyx's (RARE) Q4 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports wider-than-expected loss in the fourth quarter of 2021 while revenues miss estimates.

Ultragenyx (RARE) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -35.61% and 0.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regeneron (REGN) Collaborates With Ultragenyx for Evkeeza

by Zacks Equity Research

Regeneron (REGN) teams up with Ultragenyx Pharmaceutical to commercialize and distribute Evkeeza (evinacumab) outside the United States.

Why Is Ultragenyx (RARE) Down 11.4% Since Last Earnings Report?

by Zacks Equity Research

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ultragenyx (RARE) Begins Dosing in Phase I/II Study of UX053

by Zacks Equity Research

Ultragenyx (RARE) doses the first patient in a phase I/II study evaluating its investigational mRNA candidate, UX053, for treating glycogen storage disease type III.

Ultragenyx's (RARE) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports narrower-than-expected loss in the third quarter of 2021 while revenues surpass estimates.

Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of 24.48% and 4.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Ultragenyx (RARE) Q3 Earnings Expected to Decline

by Zacks Equity Research

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) Begins Angelman Syndrome Study in Canada

by Zacks Equity Research

Ultragenyx (RARE) and GeneTx Biotherapeutics dose the first patient in a phase I/II study on GTX-102 for treating patients with Angelman syndrome in Canada.

Ultragenyx (RARE) Reports FDA Removal of Clinical Hold on Study

by Zacks Equity Research

Ultragenyx (RARE) and GeneTx Biotherapeutics to start dosing in the phase I/II study on GTX-102 for treating pediatric patients with Angelman syndrome after the FDA removes its clinical hold on the same.